Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2019 - ResearchAndMarkets.com

May 8, 2019

DUBLIN--(BUSINESS WIRE)--May 8, 2019--The “Paroxysmal Nocturnal Hemoglobinuria - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Paroxysmal Nocturnal Hemoglobinuria development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for Paroxysmal Nocturnal Hemoglobinuria
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Paroxysmal Nocturnal Hemoglobinuria
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Paroxysmal Nocturnal Hemoglobinuria
  • The report also covers the dormant and discontinued pipeline projects related to Paroxysmal Nocturnal Hemoglobinuria

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Paroxysmal Nocturnal Hemoglobinuria to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Paroxysmal Nocturnal Hemoglobinuria therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Paroxysmal Nocturnal Hemoglobinuria Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • Achillion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Apellis Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • ISU ABXIS Co Ltd
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Omeros Corp
  • Ra Pharmaceuticals Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/plxhzd

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005685/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/08/2019 01:14 PM/DISC: 05/08/2019 01:14 PM